Search
Zenocutuzumab
go.drugbank.com/drugs/DB15559ApprovedInvestigational[L56179] This approval was expedited following receipt of an FDA Commissioner’s National Priority Voucher. … [L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma.
Siponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigational[L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA … It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020.
Categories: Sphingosine 1-phosphate Receptor Modulator, Sphingosine 1 Phosphate Receptor ModulatorsButabarbital
go.drugbank.com/drugs/DB00237ApprovedIllicitWithdrawn[A201977,L13613] Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines. … [A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.[L13613]
Beta carotene
go.drugbank.com/drugs/DB06755ApprovedNutraceutical[T158] Under the FDA, beta-carotene is considered as a generally recognized as safe substance (GRAS).[L2191]
Mixtures: BiO-LiFE Anti-FR+Selenium Tablets, Prenatabs FALeucine-rich repeat-containing G protein-coupled receptor 5
go.drugbank.com/bio_entities/BE0010835TargetHumansReceptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle.
Polypeptides: Leucine-rich repeat-containing G protein-coupled receptor 5Synonyms: G protein-coupled receptor 49, G protein-coupled receptor 67Brexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalAs of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically
Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator, Neuroactive Steroid Gamma-Aminobutyric Acid (GABA) A Receptor Positive ModulatorsCapsaicin
go.drugbank.com/drugs/DB06774ApprovedInvestigationalThe most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.
Paritaprevir
go.drugbank.com/drugs/DB09297ApprovedInvestigationalWithin Canada and the United States, paritaprevir is currently available in three fixed dose products: Viekira Pak (FDA), Technivie (FDA and Health Canada), and Holkira Pak (Health Canada). … More specifically, paritaprevir prevents viral replication by inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label].
Ombitasvir
go.drugbank.com/drugs/DB09296ApprovedInvestigationalOmbitasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly [FDA Label]. … Ombutasvir is also available as a fixed-dose combination product with [DB09297] and [DB00503] as the FDA- and Health Canada-approved product Technivie.
Sarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigationalarthritis (RA) in combination with methotrexate. … [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid
Categories: Interleukin-6 Receptor Antagonist